EA201290558A1 - Агонисты mglu2 - Google Patents

Агонисты mglu2

Info

Publication number
EA201290558A1
EA201290558A1 EA201290558A EA201290558A EA201290558A1 EA 201290558 A1 EA201290558 A1 EA 201290558A1 EA 201290558 A EA201290558 A EA 201290558A EA 201290558 A EA201290558 A EA 201290558A EA 201290558 A1 EA201290558 A1 EA 201290558A1
Authority
EA
Eurasian Patent Office
Prior art keywords
agonists
mglu2
schizophrenia
depression
represented
Prior art date
Application number
EA201290558A
Other languages
English (en)
Other versions
EA020229B1 (ru
Inventor
Джеймс Аллен Монн
Лурдес Пьето
Лорена Табоада Мартинес
Карлос Монтеро Сальгадо
Брюс Вилльям Шоу
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42026702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201290558(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201290558A1 publication Critical patent/EA201290558A1/ru
Publication of EA020229B1 publication Critical patent/EA020229B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Abstract

Согласно настоящему изобретению предложены новые агонисты mGlu2, подходящие для лечения биполярного расстройства, шизофрении, депрессии и генерализированного тревожного расстройства. Новые агонисты представлены формулой
EA201290558A 2009-12-21 2010-12-15 АГОНИСТЫ mGlu2 EA020229B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09382290 2009-12-21
US30523910P 2010-02-17 2010-02-17
PCT/US2010/060371 WO2011084437A1 (en) 2009-12-21 2010-12-15 Mglu2 agonists

Publications (2)

Publication Number Publication Date
EA201290558A1 true EA201290558A1 (ru) 2012-12-28
EA020229B1 EA020229B1 (ru) 2014-09-30

Family

ID=42026702

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201290558A EA020229B1 (ru) 2009-12-21 2010-12-15 АГОНИСТЫ mGlu2

Country Status (35)

Country Link
US (1) US8318184B2 (ru)
EP (1) EP2516406B1 (ru)
JP (1) JP5779190B2 (ru)
KR (1) KR101395356B1 (ru)
CN (1) CN102695701B (ru)
AR (1) AR079343A1 (ru)
AU (1) AU2010340039B2 (ru)
BR (1) BR112012017188B1 (ru)
CA (1) CA2784667C (ru)
CR (1) CR20120322A (ru)
CY (1) CY1114880T1 (ru)
DK (1) DK2516406T3 (ru)
DO (1) DOP2012000173A (ru)
EA (1) EA020229B1 (ru)
EC (1) ECSP12011989A (ru)
ES (1) ES2435651T3 (ru)
HK (1) HK1171228A1 (ru)
HN (1) HN2012001160A (ru)
HR (1) HRP20131052T1 (ru)
IL (1) IL220011A (ru)
JO (1) JO2978B1 (ru)
MA (1) MA33824B1 (ru)
MX (1) MX2012007332A (ru)
MY (1) MY160618A (ru)
NZ (1) NZ600305A (ru)
PE (1) PE20121688A1 (ru)
PL (1) PL2516406T3 (ru)
PT (1) PT2516406E (ru)
RS (1) RS53063B (ru)
SG (1) SG181836A1 (ru)
SI (1) SI2516406T1 (ru)
TN (1) TN2012000281A1 (ru)
TW (1) TWI477490B (ru)
UA (1) UA107684C2 (ru)
WO (1) WO2011084437A1 (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20146202B (en) 2010-02-17 2014-11-25 Takeda Pharmaceuticals Co Heteroaromatic aryl triazole derivatives as pde10a enzyme inhibitors
WO2012068041A1 (en) * 2010-11-18 2012-05-24 Eli Lilly And Company 4-SUBSTITUTED-3-BENZYLOXY-BICYCLO[3.1.0]HEXANE COMPOUNDS AS mGluR 2/3 ANTAGONISTS
AR083845A1 (es) * 2010-11-18 2013-03-27 Lilly Co Eli COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR2/3
PT2721012T (pt) * 2011-06-17 2016-07-27 Lilly Co Eli Derivados do ácido biciclo(3.1.0)hexano-2,6¿dicarboxílico como agonista do recetor mglu2
AR089718A1 (es) * 2012-02-01 2014-09-10 Lilly Co Eli AGONISTAS DE mGlu2/3
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
DK3431106T3 (da) * 2014-01-21 2021-03-15 Janssen Pharmaceutica Nv Kombinationer omfattende positive allosteriske modulatorer eller orthosteriske agonister af metabotrop glutamaterg subtype 2-receptor og anvendelse af disse
ES2860298T3 (es) 2014-01-21 2021-10-04 Janssen Pharmaceutica Nv Combinaciones que comprenden moduladores alostéricos positivos del receptor glutamatérgico metabotrópico de subtipo 2 y su uso
SI3277270T1 (sl) 2015-04-01 2022-04-29 Akebia Therapeutics, Inc. Sestavki in postopki za zdravljenje anemije

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576323A (en) * 1993-12-03 1996-11-19 Eli Lilly And Company Excitatory amino acid receptor antagonists
GB9605429D0 (en) * 1995-11-16 1996-05-15 Lilly Co Eli Excitatory amino acid receptor antagonists
US5688826A (en) 1995-11-16 1997-11-18 Eli Lilly And Company Excitatory amino acid derivatives
ZA983930B (en) 1997-05-14 1999-11-08 Lilly Co Eli Excitatory amino acid receptor modulators.
IL156364A0 (en) * 2001-01-11 2004-01-04 Lilly Co Eli Prodrugs of excitatory amino acids
WO2002055485A1 (en) * 2001-01-11 2002-07-18 Eli Lilly And Company Prodrugs of excitatory amino acids
WO2002068380A1 (en) * 2001-02-22 2002-09-06 Eli Lilly And Company Synthetic excitatory amino acids
PT1517915E (pt) * 2002-06-11 2009-04-09 Lilly Co Eli Pró-drogas de amino ácidos de excitação
WO2005000790A1 (ja) * 2003-06-26 2005-01-06 Taisho Pharmaceutical Co., Ltd. ２－アミノビシクロ[３．１．０]ヘキサン－２，６－ジカルボン酸誘導体
WO2012068041A1 (en) * 2010-11-18 2012-05-24 Eli Lilly And Company 4-SUBSTITUTED-3-BENZYLOXY-BICYCLO[3.1.0]HEXANE COMPOUNDS AS mGluR 2/3 ANTAGONISTS
AR083845A1 (es) * 2010-11-18 2013-03-27 Lilly Co Eli COMPUESTOS 3-FENILSULFANILMETIL-BICICLO[3.1.0]HEXANO 4-SUSTITUIDOS COMO ANTAGONISTAS DE mGluR2/3

Also Published As

Publication number Publication date
UA107684C2 (xx) 2015-02-10
RS53063B (en) 2014-04-30
CN102695701B (zh) 2014-10-01
TN2012000281A1 (en) 2013-12-12
AR079343A1 (es) 2012-01-18
IL220011A (en) 2014-03-31
HN2012001160A (es) 2015-08-24
CY1114880T1 (el) 2016-12-14
EA020229B1 (ru) 2014-09-30
CA2784667A1 (en) 2011-07-14
AU2010340039A1 (en) 2012-08-09
CN102695701A (zh) 2012-09-26
WO2011084437A1 (en) 2011-07-14
PT2516406E (pt) 2013-10-10
AU2010340039B2 (en) 2014-03-20
CA2784667C (en) 2014-11-18
DK2516406T3 (da) 2013-10-14
ES2435651T3 (es) 2013-12-20
SI2516406T1 (sl) 2013-11-29
BR112012017188B1 (pt) 2021-06-22
US20110152334A1 (en) 2011-06-23
BR112012017188A8 (pt) 2016-10-04
TW201144290A (en) 2011-12-16
SG181836A1 (en) 2012-08-30
MA33824B1 (fr) 2012-12-03
NZ600305A (en) 2014-01-31
ECSP12011989A (es) 2012-07-31
IL220011A0 (en) 2012-07-31
BR112012017188A2 (pt) 2016-03-22
EP2516406B1 (en) 2013-09-18
JP5779190B2 (ja) 2015-09-16
US8318184B2 (en) 2012-11-27
DOP2012000173A (es) 2012-11-30
KR101395356B1 (ko) 2014-05-14
JO2978B1 (en) 2016-03-15
EP2516406A1 (en) 2012-10-31
PE20121688A1 (es) 2012-12-05
MX2012007332A (es) 2012-07-20
MY160618A (en) 2017-03-15
HRP20131052T1 (hr) 2013-12-06
CR20120322A (es) 2012-07-10
TWI477490B (zh) 2015-03-21
KR20120094056A (ko) 2012-08-23
JP2013514974A (ja) 2013-05-02
HK1171228A1 (en) 2013-03-22
PL2516406T3 (pl) 2014-03-31

Similar Documents

Publication Publication Date Title
EA201290558A1 (ru) Агонисты mglu2
EA201270149A1 (ru) Ингибиторы bace
CY1119515T1 (el) Οξαζολο υποκατεστημενα ινδαζολια ως αναστολεις ρι3-κινασης
PH12016501192A1 (en) Tetrahydropyridopyrazines modulators of gpr6
UY34352A (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de la idh mutante
EA201590292A1 (ru) Соединения, которые являются sip-модулирующими агентами и/или atx-модулирующими агентами
CR10955A (es) Nuevo procedimiento de sintesis de la agomelatina
MX2014015049A (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos.
MX358376B (es) Nuevos derivados dihidroquinolina-2-ona.
CR10960A (es) Nuevo procedimiento de sintesis de la agomelatina
CO6821958A2 (es) Tetrahidroquinolinas condensadas con cicloalquilo como moduladores de receptores de crth2
EA201000069A1 (ru) Новые гербициды
CR10934A (es) Nuevo procedimiento de sintesis de la agomelatina
CU24289B1 (es) Nuevo procedimiento para la síntesis de la agomelatina
BR112013028368A2 (pt) novos compostos de hexahidrociclopentapirrolona, hexahidropirrolopirrolona, octahidropirrolopiridinona e octahidropiridinona
EA201391700A1 (ru) АГОНИСТЫ РЕЦЕПТОРА mGlu2
CU20130087A7 (es) Nuevo procedimiento de síntesis de la agomelatina
TR201110248A2 (tr) 3,7-Bis(2-hydroxyethyl) icaritin bileşeninin gribal enfeksiyon tedavisinde kullanımı.
EA201300141A1 (ru) Алкилзамещенные 3-гидроксипиридины для лечения депрессии

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ BY KG MD TJ TM